IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

Introduction: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. The ongoing phase 3 PROTECT trial examines sparsentan in adults with IgA nephropathy (IgAN). Methods: The PROTECT tri...

Full description

Bibliographic Details
Main Authors: Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E. Alpers, Stewart Bieler, Ping He, Jula Inrig, Radko Komers, Hiddo J.L. Heerspink, Alex Mercer, Irene L. Noronha, Jai Radhakrishnan, Michelle N. Rheault, William Rote, Howard Trachtman, Hernán Trimarchi, Vlado Perkovic
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Kidney International Reports
Subjects:
dual endothelin angiotensin receptor antagonist
ethnicity
immunoglobulin A nephropathy
race
randomized controlled clinical trial
sparsentan
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024923011956

Internet

http://www.sciencedirect.com/science/article/pii/S2468024923011956

Similar Items